ALDOB K87 Lactylation Rewires Mitochondria in Pulmonary Hypertension

Pulmonary hypertension (PH) is marked by progressive pulmonary vascular remodeling, narrowing or occlusion of the pulmonary circulation, and eventual right-ventricular failure. The reference study, ALDOB K87 lactylation drives mitochondrial fission and metabolic reprogramming in pulmonary hypertension, addresses an important gap in this field: how hypoxia-associated metabolic changes are converted into persistent structural abnormalities in pulmonary artery smooth muscle cells (PASMCs). The article is available as an article in press in Communications Biology through the reference study and DOI record.

Study Background and Research Question

Existing PH research has established that PASMCs undergo a metabolic shift from oxidative phosphorylation toward aerobic glycolysis, often described as a Warburg-like phenotype. This change can supply energy and biosynthetic intermediates for abnormal cell growth, migration, and phenotypic switching. It also increases lactate production. Rather than treating lactate solely as a metabolic waste product, the study investigates whether lactate can modify nonhistone proteins through lysine lactylation and thereby influence organelle behavior.

The central question was whether a specific lactylated protein could connect glycolytic reprogramming to mitochondrial dynamics and vascular remodeling. The authors focused on aldolase B (ALDOB), a glycolytic enzyme, and particularly on lactylation at lysine 87. This site-centered approach is more informative than measuring total lactate alone because it asks whether a defined post-translational modification has a causal role in PH-associated cellular pathology.

Key Innovation from the Reference Study

The principal innovation is the proposed lactate–ALDOB–DRP1 axis. According to the reference study, hypoxia increases ALDOB K87 lactylation in human PASMCs. The modified ALDOB is associated with increased glycolytic flux and lactate accumulation, creating a feed-forward relationship in which metabolic rewiring sustains the modification itself.

The work then extends this metabolic observation into mitochondrial biology. ALDOB lactylation promotes recruitment of dynamin-related protein 1 (DRP1) to mitochondria through sentrin/SUMO-specific peptidase 3 (SENP3)-mediated DRP1 deSUMOylation. Increased mitochondrial DRP1 activity favors fragmentation, a form of mitochondrial fission linked in this model to PASMC proliferation, migration, and phenotypic switching. This mechanism places a nonhistone post-translational modification upstream of both mitochondrial morphology and vascular cell behavior.

A second important element is the identification of Sirtuin 1 (SIRT1) as an ALDOB delactylase. Reduced SIRT1 in PH may therefore allow ALDOB K87 lactylation to persist. The resulting model is not simply that hypoxia raises lactate; it is that altered lactate handling, site-specific protein modification, impaired removal of that modification, and mitochondrial remodeling form an interconnected pathogenic circuit.

Methods and Experimental Design Insights

Model-to-mechanism design

The study used an integrated strategy rather than relying on a single model. Lactylomic profiling was performed in hypoxic human PASMCs to identify candidate lactylation sites associated with the disease-relevant stimulus. ALDOB K87 emerged as a prominent candidate and was then examined in rodent PH models, providing in vivo validation of the cellular finding.

The mechanistic experiments combined several complementary perturbations. Genetic or pharmacological suppression of ALDOB lactylation was used to test whether the modification was functionally required. Lactylation-mimetic ALDOB mutants were used in the opposite direction to examine whether enhanced modification could worsen the phenotype. The authors also evaluated the ALDOB–DRP1 relationship, mitochondrial fragmentation, SIRT1 status, and PASMC behaviors. This combination of discovery profiling, molecular validation, gain-of-function testing, loss-of-function testing, and animal analysis strengthens causal interpretation.

Protocol Parameters

• Cellular disease stimulus: Use hypoxic human PASMCs when testing whether oxygen limitation induces ALDOB K87 lactylation and associated metabolic changes; this reflects the primary cellular context reported in the study.
• Candidate-site confirmation: Treat lactylomic profiling as a discovery step and independently validate ALDOB K87 before assigning a mechanistic role to the site.
• Mitochondrial readout: Pair ALDOB-lactylation measurements with mitochondrial morphology or fission readouts and DRP1 localization, rather than interpreting a change in glycolysis as evidence of mitochondrial causality.
• Causal perturbation: Include both suppression of ALDOB lactylation and a lactylation-mimetic condition where experimentally appropriate. The former tests necessity, whereas the latter tests whether increased modification is sufficient to aggravate the phenotype.
• Phenotypic endpoints: Assess PASMC proliferation, migration, and phenotypic switching as related but distinct outcomes. A single proliferation measurement cannot represent the full vascular-remodeling phenotype.
• Model translation: Compare cell-based observations with a rodent PH model and retain untreated, hypoxic or disease-model, and pathway-perturbed groups so that molecular effects can be distinguished from general toxicity.

The last three parameters are practical design recommendations derived from the study’s logic, not additional numerical conditions reported by the authors. In particular, a follow-up experiment should avoid treating an exogenous mitogen response as interchangeable with the lactate-dependent ALDOB mechanism.

Core Findings and Why They Matter

ALDOB K87 is positioned at the metabolic control point

The study reports that hypoxia-induced ALDOB K87 lactylation amplifies glycolytic activity and lactate accumulation. This finding is meaningful because ALDOB is already situated within glucose metabolism; modification at this enzyme can therefore provide a direct biochemical route by which the metabolic state of a PASMC influences downstream signaling. The proposed positive feedback may help explain why pathological metabolic remodeling becomes self-reinforcing rather than disappearing when the initial stress is reduced.

Mitochondrial fission links metabolism to cell behavior

Fragmented mitochondria are often observed in disease-associated vascular cells, but an observation alone does not establish why fragmentation occurs or what it accomplishes. Here, the authors connect ALDOB lactylation to DRP1 recruitment through SENP3-dependent deSUMOylation. In the reported model, this pathway provides a mechanistic bridge from a glycolytic post-translational modification to altered mitochondrial dynamics.

The downstream consequences extend beyond organelle morphology. Suppressing ALDOB lactylation attenuated mitochondrial fission and PH progression in vivo, while lactylation-mimetic mutants aggravated disease-associated phenotypes. The findings also associate the pathway with PASMC proliferation, migration, and phenotypic switching, all of which are relevant to pulmonary vascular remodeling. The value of the result is therefore systems-level: it integrates metabolism, post-translational regulation, organelle dynamics, and tissue pathology in one experimentally testable sequence.

SIRT1 introduces a regulatory counterweight

Identifying SIRT1 as an ALDOB delactylase adds an additional layer of control. The reported reduction of SIRT1 in PH is consistent with a setting in which lactylated ALDOB accumulates because both the modifying environment and the capacity for removal are altered. This does not establish that SIRT1 alone determines disease severity, but it provides a plausible regulatory checkpoint for experiments that examine the persistence and reversibility of ALDOB K87 lactylation.

Comparison with Existing Internal Articles

The internal article ALDOB K87 Lactylation Rewires Mitochondria in Pulmonary Hypertension offers a concise interpretation of the same mechanistic discovery, emphasizing the connection between lactate signaling, mitochondrial fission, and PASMC proliferation. It is useful as a conceptual overview, whereas the reference paper is the primary source for the integrated profiling, perturbation experiments, and rodent validation.

A different perspective appears in PDGF-BB in Pulmonary Hypertension Assays. That article translates the PH mechanism into assay-design considerations, particularly the need to distinguish a conventional mitogenic stimulus from lactate-driven mitochondrial remodeling. This is complementary rather than confirmatory: the reference study does not establish PDGF-BB as part of the ALDOB K87 pathway.

The systems-level framing in PDGF-BB, Murine Recombinant Protein: Systems Biology & PH Remodeling can help researchers place exogenous growth-factor responses alongside metabolic and mitochondrial endpoints. However, such an assay framework should be interpreted as an experimental extension. It should not be presented as evidence that PDGF-BB causes ALDOB lactylation, DRP1 deSUMOylation, or the specific disease mechanism reported by Liu and colleagues.

Limitations and Transferability

Several limitations should shape interpretation. First, the supplied reference is an article-in-press version that may undergo editorial changes before final publication. Experimental details, figure annotations, and wording should therefore be checked against the final record when available. Second, hypoxic human PASMCs reproduce an important component of PH biology but cannot capture the immune, endothelial, hemodynamic, and right-ventricular interactions present in patients.

Third, rodent validation improves biological relevance but does not guarantee that ALDOB K87 lactylation, SIRT1 regulation, or SENP3–DRP1 coupling has the same magnitude across human PH subtypes. PH is heterogeneous, and hypoxia-associated disease may not represent all clinical forms. Fourth, pharmacological suppression can have off-target effects unless target engagement and pathway selectivity are demonstrated. Genetic suppression and lactylation-mimetic mutants provide stronger causal support, but engineered mutants may not reproduce the structural and dynamic properties of endogenous lactylation.

Finally, mitochondrial fragmentation and PASMC proliferation are related but not identical endpoints. A treatment that reduces proliferation may act through cell-cycle control without correcting mitochondrial dysfunction, while a treatment that changes mitochondrial morphology may not reverse vascular remodeling. Follow-up studies should therefore measure the molecular modification, DRP1 behavior, mitochondrial structure, metabolism, and cellular phenotype in parallel.

Research Support Resources

For a separate mitogenic comparator in vascular-cell experiments, researchers can use PDGF-BB, murine recombinant protein (SKU P1048). This recombinant PDGF-BB is described as a non-glycosylated, 109-amino-acid protein expressed in Escherichia coli, with a reported molecular weight of 24.4 kDa and purity of at least 95% according to the product information. It signals through PDGFR-α and PDGFR-β and can provide a defined context for studying PDGF-BB mitogen activity, smooth muscle cell proliferation, or a cell proliferation assay with PDGF-BB alongside, but not as a substitute for, the lactate–ALDOB–DRP1 mechanism. The product information reports dose-dependent BALB/c 3T3 proliferation with an ED50 below 2 ng/ml, endotoxin below 0.1 ng/μg, and recommends reconstitution in sterile 100 mM acetic acid containing 0.1% BSA at 0.1–1.0 mg/ml. These specifications support controlled research use of a growth-factor comparator when investigating PDGFR-α and PDGFR-β signaling in relation to metabolic remodeling.